The Europan Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended four biologics, among them three biosimilars, one monoclonal antibody as well as two targeted therapies for EU market authorisation.
Neurology specialist Celgene has nailed down access to Evotecs induced pluripotent stem cell (iPSC) platform for screening of compounds against neurodegenerative diseases.
Spanish world market leader for nucleic acid-based virus screening in blood banks, Grifols, has confirmed the purchase price for US-based Hologic’s NAT donor screening unit.
Finnish theranostics specialist Orion Corporation is set to fill its oncology pipeline through a drug development alliance.
Dutch-German molecular diagostics specialist Curetis has bagged debt finanancing from the European Investment Bank (EIB) to expand its automated multiplex PCR platform Univero. The company will receive €10m immediately. Further €15m are milestone-dependent.
While competitor Eli Lilly has abandoned commercialisation of its Alzheimer’s therapy solanezumab due to lack of efficacy in a pivotal Phase III study, Genentech has tabled data supporting further development of its Phase III drug crenezumab. The anti-Abeta antibody is highly homologous to solanezumab.
French immunotherapy company TxCell has teamed up with Inserm Transfert, the tech transfer subsidiary of the French National Institute of Health and Medical Research Inserm, to develop immuno-suppressive regulatory T cells.
UK researchers have identified a highly conserved target structure that can be directed to rush dividing cancer cells into premature division and cell death.
Merck KGaA has expanded its portfolio of blood-based RAS diagnostics for use in patient stratification. After kicking off testing with Sysmex Inostics’ CE-marked OncoBEAM RAS CRC liquid biopsy assay last year, the German drug maker welcomed the launch of a second blood-based test to detect KRAS mutations in patients with colorectal cancer (CRC): Biocartis’ Idylla ctKRAS Mutation Assay.
Euronext Brussels-noted adipose stem cell player TiGenix NV wants to offer 2.75 million American Depositary Shares (ADS) in an IPO at Nasdaq Global Market representing 55 million of its ordinary shares which had went up from €0.91 yesterday to €0.96 (10.a.m.).